Please assess the completion status of the following clinical trial:

Trial Title: Study of Gemcitabine and Abraxane for Pancreas Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed metastatic adenocarcinoma of the pancreas~* Progression on first line non-gemcitabine based therapy for metastatic or relapsed disease~* Radiographically measurable or evaluable disease~* Age \>/= 18 years~* ECOG performance status 0-2~* Adequate hepatic, bone marrow and renal function~Exclusion Criteria:~* Prior gemcitabine-based chemotherapy in the first line setting~* No active severe infection, or known chronic infection with HIV or hepatitis B virus~* No cardiovascular disease problems including unstable angina, therapy for life-threatening ventricular arrhythmia, or myocardial infarction, stroke, or congestive heart failure within the last 6 months~* No women who are pregnant or breastfeeding, and no women of childbearing potential without using dual forms of contraception~* Patients with known CNS metastases~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine or nab-paclitaxel~* Anticipated patient survival under 2 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine/abraxane (Type: EXPERIMENTAL): Gemcitabine and Abraxane

Based on this trial design, predict the completion outcome and termination type (if applicable).